Limosilactobacillus reuteri DSMZ17648 in Helicobacter pylori infection: clinical information and mechanisms: Research Article

JOSE ANGEL MARANON; Alejandra Hernández-Bueno

doi:10.58372/2835-6276.1165

Authors

JOSE ANGEL MARANON TRADICHEM GROUP
Alejandra Hernández-Bueno

DOI:

https://doi.org/10.58372/2835-6276.1165

Keywords:

Helicobacter pylori, ulcer disease, gastritis, antimicrobial resistance, probiotics, postbiotics, Lactobacillus reuteri

Abstract

Objectives: Helicobacter pylori is a ubiquitous organism that is present in about 50% of the global population. Chronic infection with Helicobacter pylori causes atrophic and even metaplastic changes in the stomach, and it has a known association with peptic ulcer diseases. Due to the increasing issue of antimicrobial resistance, the effectiveness of current first-line treatments for Helicobacter pylori is diminishing, resulting in decreased eradication rates. Limosilactobacillus reuteri spray-dried strain DSMZ17648 (Pylopass™) constitutes a promising therapeutic approach to enhance bacterial eradication, consequently reducing the risk of developing associated diseases.

Methods: the literature in this review was found by searching in databases including PubMed, clinicaltrials.gov and Google Scholar.

Results: clinical evidence has shown that Limosilactobacillus reuteri DSMZ17648 reduces H. pylori load in the stomach in both adults and children, improves gastrointestinal symptoms, minimizes antibiotic side effects, and decreases inflammation and atrophy of the gastric mucosa. Long-term intervention with Limosilactobacillus reuteri DSMZ17648 had a similar eradication rate to standard triple therapy, and supplementation has been found to increase the eradication rates of antibiotic therapy.

Conclusion: Limosilactobacillus reuteri DSMZ17648 represents a novel therapeutic approach that opens a new path to the use of postbiotics against H. pylori, contributing indirectly to the fight against antibiotic resistances. The spray-drying technology makes Lactobacillus reuteri DSMZ17648 easy to preserve and transport, establishing a potential solution for treating H. pylori infections in developing countries, where antibiotic resistance rates are the highest worldwide.

References

Buzás GM. [History of the discovery of Helicobacter pylori]. Orvostorteneti Kozlemenyek. 2004;49(3-4):45-56.

Ertem D. Clinical practice: Helicobacter pylori infection in childhood. Eur J Pediatr. 2013;172(11):1427-1434. doi:10.1007/s00431-012-1823-4

Mehrotra T, Devi TB, Kumar S, et al. Antimicrobial resistance and virulence in Helicobacter pylori: Genomic insights. Genomics. 2021;113(6):3951-3966. doi:10.1016/j.ygeno.2021.10.002

Dube C, Tanih NF, Ndip RN. Helicobacter pylori in water sources: a global environmental health concern. Rev Environ Health. 2009;24(1):1-14. doi:10.1515/reveh.2009.24.1.1

Madinier IM, Fosse TM, Monteil RA. Oral Carriage of Helicobacter pylori: A Review. J Periodontol. 1997;68(1):2-6. doi:10.1902/jop.1997.68.1.2

Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Tauxe RV. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology. 1992;102(1):41-46. doi:10.1016/0016-5085(92)91782-y

Banić M, Franceschi F, Babić Z, Gasbarrini A. Extragastric Manifestations of Helicobacter pylori Infection. Helicobacter. 2012;17(s1):49-55. doi:10.1111/j.1523-5378.2012.00983.x

Jung HK, Kang SJ, Lee YC, et al. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med. 2021;36(4):807-838. doi:10.3904/kjim.2020.701

He J, Liu Y, Ouyang Q, et al. Helicobacter pylori and unignorable extragastric diseases: Mechanism and implications. Front Microbiol. 2022;13. doi:10.3389/fmicb.2022.972777

Candelli M, Franza L, Cianci R, et al. The Interplay between Helicobacter pylori and Gut Microbiota in Non-Gastrointestinal Disorders: A Special Focus on Atherosclerosis. Int J Mol Sci. 2023;24(24):17520. doi:10.3390/ijms242417520

Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-429. doi:10.1053/j.gastro.2017.04.022

Nyssen OP, Bordin D, Tepes B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40-54. doi:10.1136/gutjnl-2020-321372

Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-239. doi:10.1038/ajg.2016.563

Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther. 2017;24(6):e751-e757. doi:10.1097/MJT.0000000000000389

Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69.e14. doi:10.1053/j.gastro.2016.04.006

Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514-533. doi:10.1111/apt.13497

Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148(4):719-731.e3. doi:10.1053/j.gastro.2015.01.040

Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-1367. doi:10.1136/gutjnl-2015-309252

Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut. 2006;55(12):1711-1716. doi:10.1136/gut.2006.091272

O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Government of the United Kingdom; 2016. Accessed March 6, 2024. https://apo.org.au/node/63983

Ng HY, Leung WK, Cheung KS. Antibiotic Resistance, Susceptibility Testing and Stewardship in Helicobacter pylori Infection. Int J Mol Sci. 2023;24(14):11708. doi:10.3390/ijms241411708

Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol. 2015;21(37):10644-10653. doi:10.3748/wjg.v21.i37.10644

Patel A, Shah N, Prajapati JB. Clinical application of probiotics in the treatment of Helicobacter pylori infection--a brief review. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. 2014;47(5):429-437. doi:10.1016/j.jmii.2013.03.010

Holz C. PylopassTM (L. reuteri DSMZ 17648) Quality Information. ORGANOBALANCE GmbH.

Mehling H, Busjahn A. Non-viable Lactobacillus reuteri DSMZ 17648 (PylopassTM) as a new approach to Helicobacter pylori control in humans. Nutrients. 2013;5(8):3062-3073. doi:10.3390/nu5083062

Holz C. Specific co-aggregation of Helicobacter pylori and Lactobacillus reuteri DSM 17648 under gastric conditions in vitro.

Holz C, Busjahn A, Mehling H, et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics Antimicrob Proteins. 2015;7(2):91-100. doi:10.1007/s12602-014-9181-3

Bordin D, Yanova O, Voinovan I, et al. The efficiency and safety of probiotic bacteria Lactobacillus reuteri DSMZ17648 (HELINORM) in patients infected with H.pylori without absolute indications for eradication therapy: results of the study. Central Research Institute of Gastroenterology GBUZ “Moscow Clinical Research Center” DZ Moscow.

Parolova N, Kornienko E, Antonov P, Egorov Mikhail Gorbunov E, Dmitrienko M. An Innovative Approach in the Treatment of H. pylori Infection in Children. In: Vol 22. ; 2015.

Uspienskiy Y, Formin Y, Ivanov S, Menaker I. Evolution in eradication therapy of HP-associated diseases: beyond the standards? RMZ Med Obozrenie. 2016;197:1144-1152.

Bordin D, Voinovan I, Khomeriki S. The efficacy and the safety of Lactobacillus reuteri DSMZ17648 in the treatment of Helicobacter pylori positive patients. In: ; 2017.

Buckley M, Lacey S, Doolan A, Goodbody E, Seamans K. The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study. BMC Nutr. 2018;4:48. doi:10.1186/s40795-018-0257-4

Muresan IAP, Pop LL, Dumitrascu DL. Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia. Med Pharm Rep. 2019;92(4):352-355. doi:10.15386/mpr-1375

Kornienko EA, Parolova NI, Ivanov SV, et al. Gastric microbiota and probiotics opportunities in helicobacter pylori eradication in children. Gastroenterol Hepatol Open Access. 2020;11(1):13-23. doi:10.15406/ghoa.2020.11.00407

Parth K, Prudhivi R, Palatheeya S, et al. Efficacy of Lactobacillus reuteri Supplementation in Eradication of H. pylori: A Comparison Study with Triple Drug Therapy. J Pharm Res Int. Published online December 1, 2021:151-159. doi:10.9734/jpri/2021/v33i52B33611

Yang C, Liang L, Lv P, et al. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial. Helicobacter. 2021;26(6):e12856. doi:10.1111/hel.12856

Naghibzadeh N, Salmani F, Nomiri S, Tavakoli T. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial. BMC Gastroenterol. 2022;22(1):107. doi:10.1186/s12876-022-02187-z

Ismail NI, Nawawi KNM, Hsin DCC, et al. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2023;28(6):e13017. doi:10.1111/hel.13017

Malfertheiner P. Compliance, Adverse Events and Antibiotic Resistance in Helicobacter pylori Treatment. Scand J Gastroenterol. 1993;28(sup196):34-37. doi:10.3109/00365529309098341